A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer

Author(s):
Dijkgraaf, E.M.; Santegoets, S.J.A.M.; Reyners, A.K.L.; Goedemans, R.; Nijman, H.W.; Poelgeest, M.I.E. van; Erkel, A.R. van; Smit, V.T.H.B.M. (0000-0003-3730-5652); Daemen, T.A.H.H.; Hoeven, J.J.M. van der (0000-0003-1117-1959); Melief, C.J.M.; Welters, M.J.P.; Kroep, J.R.; Burg, S.H. van der (0000-0002-6556-0354)
Published
2015
Publication type
Article / Letter to editor
ovarian cancerp53immunotherapychemoresistancetumor immunity
Date issued
2015-10-13
Language
English
Is part of
Oncotarget (2015), Vol. 6, no. 31, p. 32228-32243
hdl
1887/106514
doi
10.18632/oncotarget.4772